Skip to content
← Lobby register
DS
Other

Daiichi Sankyo Europe GmbH

🇪🇺 GERMANYRegistered 01/03 staff
Disclosed budget
€900,000 — €999,999
Meetings 12mo
3
Policy files
0
Accredited passes
1

Recent meetings

DateCommissioner / CabinetTopicFile
02 Oct 2025
Olivér Várhelyi
Commissioner
All pressing portfolio topicsSRC
02 Oct 2025
Jana Dabbelt
Cabinet member
All pressing portfolio topicsSRC
02 Oct 2025
Jana Dabbelt
Cabinet member
All pressing portfolio topics
04 Apr 2025
Tobias Wiesenthal
Head of Unit
Scientific roundtable discussion between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovationSRC
04 Apr 2025
Maurice Whelan
Head of Unit
Scientific roundtable discussion between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovationSRC
04 Apr 2025
Tobias Wiesenthal
Head of Unit
Scientific roundtable discussion between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovation
04 Apr 2025
Maurice Whelan
Head of Unit
Scientific roundtable discussion between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovation
06 Jun 2023
Elina Melngaile
Cabinet member
EU-Japan cooperation in R&D, EU-Japan trade partnership
06 Jun 2023
Elina Melngaile
Cabinet member
EU-Japan cooperation in R&D, EU-Japan trade partnershipSRC

Mission & Goals

Daiichi Sankyo is a research-based global pharmaceutical company headquartered in Japan with operations in more than 20 countries worldwide. The European headquarters are located in Munich; mainly active in the areas of cardiovascular diseases & oncology.

EU Legislative Interests

Daiichi Sankyo is interested in EU initiatives and political developments that relate to our focus in research, development, manufacturing and business: innovative medicines. This includes topics such as health policy, global health, , relevant pharmaceutical legislation including General Pharmaceutical Legislation, Biotech Act I, Urban Wastewater Treatment Directive, Critical Medicines Act, EU Safe Hearts Plan, clinical trials, trade, IP, environment and sustainability.

Communication Activities

Sponsorship and report of Economist World Cancer Series - session on Women Centric Breast Cancer Care. European Health Forum Gastein with session on NCD's and women's health, European Business Summit - session on EU Cardiovascular Health Plan, Online roundtable with European Cancer Organisation on breast cancer - sponsored.

Interests Represented

Promotes their own interests or the collective interests of their members

Member Of

Efpia (https://www.efpia.eu/) EPC (https://www.epc.eu/en) European Cancer Organisation (E.C.O.) (https://www.europeancancer.org/) Japanese Business Council (https://www.jbce.org/en/) All.Can (https://www.all-can.org/)

Organisation Members

https://www.daiichi-sankyo.eu/